5 hours ago
1
Dzmitry Skazau/iStock via Getty Images
Apogee Therapeutics (NASDAQ:APGE) stock fell on Monday despite the announcement that it met its main goal in part A of its mid-stage trial for APG777, an antibody treatment aimed at moderate-to-severe atopic dermatitis.
The company's shares have dropped by 16%
© FBT Company 2025. All rights are reserved
English (US) ·